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Findings from a recent qualitative study indicate that the perceived clinical relevance of computer-
generated STOPP/START recommendations was a key factor affecting their implementation by 
physician prescribers caring for hospitalised older adults in the SENATOR trial. 
Aim 
To systematically evaluate the clinical relevance of these recommendations and to establish if clinical 
relevance significantly affected the implementation rate. 
Methods 
A pharmacist-physician pair retrospectively reviewed the case records for all SENATOR trial 
intervention patients at Cork University Hospital, and assigned a degree of clinical relevance for each 
STOPP/START recommendation based on a previously validated six-point scale. The chi-square test 
was used to quantify the differences in prescriber implementation rates between recommendations of 




In 204 intervention patients, the SENATOR software produced 925 STOPP/START 
recommendations. Nearly three quarters of recommendations were judged to be clinically relevant 
(73.6%); however, nearly half of these were deemed of ‘possibly low relevance’ (320/681; 47%). 
Recommendations deemed of higher clinical relevance were significantly more likely to be 
implemented than those of lower clinical relevance (p < 0.05). 
Conclusions 
A large proportion (61%) of the computer-generated STOPP/START recommendations provided 
were either of potential ‘adverse significance’, of ‘no clinical relevance’, or of ‘possibly low 
relevance’. The adjudicated clinical relevance of computer-generated medication recommendations 
significantly affects their implementation. Meticulous software refinement is required for future 
interventions of this type to increase the proportion of recommendations that are of high clinical 
relevance. This should facilitate their implementation, resulting in prescribing optimisation and 












Potentially inappropriate prescribing (PIP) remains to be highly prevalent in hospitalised older adults 
[1, 2]. Computerised interventions have been shown to reduce PIP in this patient cohort, but their 
benefit in routinely improving patient outcomes has not yet been established [3, 4]. The intervention 
in a recent multi-centre randomised controlled trial (RCT), as part of the SENATOR project 
(https://www.senator-project.eu/), involved the provision of computer-generated pharmacological and 
non-pharmacological recommendations to physician prescribers caring for hospitalised older adults, 
with the primary aim of reducing in-hospital adverse drug reactions (ADRs). The pharmacological 
recommendations in the SENATOR intervention were based on the STOPP/START criteria (version 
2) [5], drug-drug interactions, and drug-disease interactions. Interim data analysis from the trial 
showed that prescriber implementation rates of the STOPP/START recommendations were lower than 
expected across the six trial sites. O’Connor et al. had previously shown in a single-centre RCT that 
high prescriber implementation rates of STOPP/START recommendations can significantly reduce in-
hospital ADRs [6]. Thus, a qualitative interview study was run alongside the RCT to explore the 
reasons behind the low implementation rates observed [7]. Interviewees perceived that the clinical 
relevance of the recommendations was one of the key factors affecting their implementation, 
suggesting the SENATOR software was producing a high proportion of recommendations that were 
of low or doubtful clinical relevance for individual patients. However, rather than simply accepting 
these qualitative findings at face value, it would be of great significance to quantitatively corroborate 
a clear association between the relevance of recommendations and their rate of implementation. 
Therefore, the aim of this study was to systematically evaluate the clinical relevance of the computer-
generated STOPP/START recommendations in the SENATOR trial and examine if the relevance of 






Context and Study setting 
The SENATOR RCT was conducted in six large acute teaching hospitals in six European countries. 
All patients recruited were multimorbid older adults (≥65 years) who consented to their enrolment in 
the trial within 60 hours of hospital admission, who were prescribed medication for ≥3 active chronic 
medical disorders, and who had an expected length of hospital stay >48 hours. More details on patient 
eligibility criteria and other pertinent trial information are published elsewhere [8, 9].  
This study evaluating the clinical relevance of SENATOR’s STOPP/START recommendations was 
conducted in the RCT’s lead recruitment site only, Cork University Hospital (CUH) - an 810-bed 
tertiary referral centre in southern Ireland. All patients who were randomised to the intervention arm 
at this site were included in the present study. In CUH, the SENATOR software generated a paper-
based report detailing the STOPP/START recommendations, which was provided in each intervention 
patient’s paper-based clinical record, and was also sent via email to the consultant with responsibility 
for clinical care of the patient. Of the 114 STOPP/START criteria (version 2), recommendations 
based on 3 criteria were excluded from our analysis: STOPP A1, START I1, and START I2, with 
reasons for exclusion provided in the Supplementary Material. 
Data collection 
A pharmacist and physician independently and retrospectively reviewed all CUH intervention arm 
patients’ medical records, drug chart, laboratory test results, and STOPP/START recommendations. 
Through consensus agreement, the pharmacist-physician pair then assigned a degree of clinical 
relevance for each STOPP/START recommendation based on a previously validated six-point scale 
with the following categories: 0: ‘adverse significance’, 1: ‘no clinical relevance’, 2: ‘possibly low 
relevance’, 3: ‘possibly important relevance’, 4: ‘possibly very important relevance’, and 5: ‘possibly 
life-saving’ [10]. The pharmacist (KD) and physician (DC) were very familiar with the 
STOPP/START criteria and SENATOR’s computerised algorithms, and, at the time of the reviews, 
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had three years and ten years post-qualification experience respectively in optimising the 
pharmacotherapy of hospitalised older adults. 
Inter-rater reliability (IRR) was determined among a sample of three pharmacists and three physicians 
(one consultant geriatrician, and two specialist registrars - i.e. senior residents - in geriatric medicine) 
in applying the scale to independently assign a degree of clinical relevance to STOPP/START 
recommendations from twenty randomly-selected intervention cases. The study design for this IRR 
assessment is provided in the Supplementary Material. 
Data analysis  
Statistical analysis was performed using SPSS® Version 22 and Microsoft® Excel. Data on prescriber 
implementation were extracted from the RCT’s electronic case report form, whereby implementation 
was defined as the prescriber discontinuing or initiating a medication in accordance with the 
recommendation at any point prior to hospital discharge. The percentage prescriber implementation 
rates were calculated for recommendations at each degree of clinical relevance. The chi-square test 
was used to determine if there were any significant differences between i) the proportion of 
recommendations and ii) the prescriber implementation rates of recommendations at varying degrees 
of clinical relevance, with differences considered statistically significant at p < 0.05.  
In the assessment of IRR, the Fleiss kappa statistic was used to determine the agreement between all 
raters and across the subgroups of raters (i.e. pharmacists and physicians). Cohen’s kappa statistic was 
used to determine the level of agreement between the individual raters. The kappa statistic was 
interpreted according to the following ranges: slight if 0.01-0.2, fair if 0.21-0.4, moderate if 0.41-0.6, 







In CUH, there were 204 SENATOR intervention patients (51% male), with a mean age of 77.4 years 
(standard deviation [SD] 6.91; Range 65-92). In total, the SENATOR software generated 925 
STOPP/START recommendations (mean 4.5/patient; SD 2.9; range 0-17), i.e. 563 STOPP 
recommendations (mean 2.8/patient; SD 2.3; range 0-13), and 362 START recommendations (mean 
1.8/patient; SD 1.5; range 0-7).  
Clinical Relevance Evaluation 
Almost three quarters (73.6%) of recommendations were deemed to be clinically relevant i.e. assigned 
to categories 2, 3, or 4 – ‘possibly low relevance’, ‘possibly important relevance’, or ‘possibly very 
important’ relevance (Table 1). The remaining 26.4% of recommendations were either category 1, i.e. 
of ‘no clinical relevance’ (21.5%), or category 0, i.e. of possible ‘adverse significance’ to the patient 
if implemented (4.9%). No recommendations were judged to be ‘possibly life-saving’. 
When comparing the clinical relevance of STOPP and START recommendations in Table 2, there 
was a statistically significantly greater proportion of START recommendations i) of possible ‘adverse 
significance’ (7.2% versus 3.4%; p < 0.05), and ii) of ‘possibly very important relevance’ (12.2% 
versus 5.7%; p < 0.05). Conversely, there was a statistically significantly greater proportion of STOPP 
recommendations of ‘possibly low relevance’ (37.7% versus 29.8%; p < 0.05).  
Prescriber Implementation Rates 
Data on prescriber implementation were available for 884/925 (95.6%) recommendations; reasons for 
unavailable data are provided in the Supplementary Material. Table 1 illustrates the prescriber 
implementation rates for the recommendations according to each assigned category of clinical 
relevance. As the clinical relevance of recommendations increases, so too does the implementation 
rate, with statistically significant differences in implementation rates between recommendations of all 
categories identified (p < 0.05), the only exception being between recommendations of potential 
‘adverse significance’ and recommendations of ‘no clinical relevance’ (6.7% versus 11.7%; p = 0.33).  
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Inter-rater Reliability Results 
When assessing IRR in choosing the same degree of clinical relevance for recommendations, the 
Fleiss kappa coefficient was found to be fair (0.24). Kappa was higher among pharmacists (0.27) than 
among physicians (0.17). The mean Cohen’s kappa coefficient between individual raters was also 

















This is the first study to evaluate the clinical relevance of computer-generated STOPP/START 
recommendations. The key finding is that increasing clinical relevance of recommendations 
associated with significantly higher implementation rates by prescribers. Our results from this sample 
of acutely ill hospitalised multimorbid older patients show that nearly three quarters of 
STOPP/START recommendations were deemed to be clinically relevant (73.6%), whilst 
approximately one quarter of the recommendations were of ‘no clinical relevance’ or of potential 
‘adverse significance’ (26.4%). Although most STOPP/START recommendations were deemed 
‘clinically relevant’, we acknowledge that nearly half of the clinically relevant recommendations were 
deemed to have ‘possibly low relevance’, i.e. category 2 on the six-point clinical relevance scale 
(320/681; 47%). Whilst these recommendations were correctly triggered by the SENATOR software, 
they may have been addressing issues that were of minor significance at the time of hospital 
admission, when the focus may have been on the patient’s acute illness. For example, nearly half of 
all benzodiazepine-related recommendations were judged to be of possibly low relevance. Although it 
is well-known that this drug class is a common contributing factor to ADRs (principally falls) in older 
adults [12], deprescribing benzodiazepines may not have been a priority at the time the 
recommendations were provided. Recommendations like these may have been more clinically 
relevant later in the admission (such as pre-discharge), or in another setting (such as primary care or 
ambulatory care), where the patient may have been more stable, and it may have been easier to 
implement medication changes. Thus, the care setting and timing of the intervention must be key 
considerations for future studies.   
The proportion of clinically relevant computer-generated recommendations can vary widely 
depending on the healthcare setting and the medications targeted [13-16]. However, there are few 
studies in the literature that have evaluated the clinical relevance of computer-generated 
recommendations concerning medication appropriateness in hospitalised older adults. One research 
group has previously reported findings similar to ours in a pilot study, with 74.5% of computerised 
alerts deemed clinically relevant [14]. However, when medication alerts in one of their subsequent 
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studies were based on a broader set of Beers criteria [17], it was found that only 30% of the alerts 
were clinically relevant in the intervention group [15]. In contrast, we have shown in the present study 
that the STOPP/START version 2 recommendations, i.e. another broad set of criteria, had a 
substantially higher proportion of clinically relevant recommendations.  
Many of these previous studies have simply judged the computer-generated recommendations in a 
dichotomous manner - clinically relevant or not clinically relevant [14-16]. However, in the present 
study, we considered it important to transcend this and qualify clinical relevance in a more nuanced 
fashion, i.e. to assess the degree of clinical relevance, by applying a defined scale. Beaudoin et al. 
used a five-point Likert scale, ranging from 1 (not relevant) to 5 (very relevant), to evaluate the 
clinical relevance of computerised rule-based alerts concerning antimicrobials [18]; however, a 
limitation to this Likert scale is that it does not explicitly consider the possibility that the 
recommendations may be potentially inappropriate, and thereby have the potential to cause harm to 
the patient. The scale chosen for use in our study had been previously employed to assess the clinical 
relevance of pharmacist recommendations in a Belgian hospital, which found low agreement between 
evaluators (range of kappa values: 0.15-0.25) [10]. Similar agreement was found between the raters in 
our study (kappa = 0.24). Furthermore, Bech et al. found only slight agreement between raters when 
assessing the clinical relevance of drug-related problems among older patients using a five-point scale 
[19]. This lack of agreement among healthcare professionals in evaluating clinical relevance 
highlights the complexities associated with selection of appropriate pharmacotherapy in older adults 
[20].  
Our study is important in that we did not merely indicate whether the recommendations were relevant 
or not, but rather we also qualified their degree of clinical relevance. If we know that 
recommendations pertaining to certain criteria or particular drug classes are more likely to be 
clinically relevant, then we can prioritise these recommendations in future interventions. For example, 
in a hospitalised patient presenting with falls, the software should prioritise recommendations relating 
to deprescribing of benzodiazepines over those relating to proton pump inhibitors (PPIs). Provision of 
the most clinically relevant recommendations only, or ensuring that these recommendations appear as 
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priorities, should help reduce the phenomenon of ‘alert fatigue’ [21]. However, designing the 
software to take account of competing influences on clinical decision making, and ranking the 
recommendations in order of priority is a significant technical challenge [22]. This study has provided 
evidence on which recommendations may be more clinically relevant than others, and thus may 
inform ranking systems within future computerised algorithms. 
The present study corroborates the findings from the contemporaneous SENATOR qualitative study, 
which indicated that the clinical relevance of the computer-generated STOPP/START 
recommendations was a key influence on their implementation by prescribers [7]. Our results show a 
clear association between these two factors – recommendations of higher clinical relevance had a 
greater probability of being implemented by prescribers. Previous research has shown that computer-
generated recommendations that were inappropriate or erroneously triggered were unlikely to be 
adopted by physicians or were overridden within the software programme [23]. However, the 
potential risk remains that some users may blindly follow inappropriate recommendations; this 
increases the risk of error and possible patient harm [24, 25]. Therefore, such computer-generated 
recommendations should complement good clinical judgment, not replace it. 
Our results indicate that a significantly greater proportion of START recommendations were either of 
possibly very high clinical relevance or of possible adverse significance in comparison to STOPP 
recommendations. Thus, certain START recommendations had the potential to be of great benefit in 
some patients, but could have caused serious harm if implemented in other patients. This indicates a 
lack of specificity in the computerised algorithms, resulting in the identification of more supposed 
instances of PIP than actual instances [26]. However, this lack of specificity is not purely an algorithm 
issue – it could also have originated from the criteria themselves. For example, previous research has 
highlighted that some of the STOPP/START criteria contain broad definitions, e.g. START A3 
criterion (version 2) refers to “…a documented history of coronary, cerebral or peripheral vascular 
disease”. Whilst this phrasing allows the criteria to be applicable to a large proportion of older adults, 
broad definitions such as this are more susceptible to clinician interpretation [27]. Thus, some criteria 
may not be as explicit as they should be for the purposes of designing computerised algorithms, and 
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previous research groups have outlined some of the complexities encountered in this process [27, 28]. 
Further iterations of STOPP/START criteria will likely need to be much more specific, especially if 
the intention is to incorporate them into computerised algorithms, which should facilitate the 
production of more clinically relevant recommendations that are tailored to individual patients.  
However, simply producing clinically relevant STOPP/START recommendations does not guarantee 
their uptake; the medium through which the recommendations are delivered to prescribers also 
significantly affects their implementation [29]. In the present study, we have found that even the 
recommendations deemed to have ‘possibly very important relevance’ were not implemented 30% of 
the time. One reason for this may have been due to the production of a high proportion of 
recommendations that were of potential adverse significance, not clinically relevant, or of low clinical 
relevance (61% of recommendations). These may, unwittingly, have undermined the trustworthiness 
of the SENATOR advice reports, and resulted in decreased engagement by clinicians with the most 
important recommendations [7]. Increasing the proportion of recommendations of higher clinical 
relevance will be essential in minimising user fatigue with future computerised interventions, and 
enhancing the likelihood of clinically important recommendations being implemented.  
As with many studies of this type, they are limited by their retrospective design, and the subjectivity 
of raters must be considered as a potential source of bias. This is the first study that the authors are 
aware of which determines the IRR among healthcare professionals in evaluating the clinical 
relevance of computer-generated STOPP/START recommendations. However, failure to achieve high 
IRR may have been due to the scale used; it has been previously shown that rating scales with poor 
IRR are likely to result in low estimates of IRR in subsequent studies [30]. Furthermore, a scale with 
fewer categories or more specific categories would allow less room for discrepancy between raters, 
and should produce a higher IRR kappa value. Agreement may have been affected by raters simply 






This quantifiably substantiates the findings from a recent qualitative study, which suggested that the 
clinical relevance of the STOPP/START recommendations in the SENATOR intervention was one of 
the key influences affecting their implementation. The present study shows that a large proportion 
(61%) of the STOPP/START recommendations provided were either of potentially adverse 
significance, irrelevant, or of low clinical relevance for the individual patients at the point of hospital 
admission. Recommendations of higher clinical relevance had significantly enhanced prescriber 
implementation rates. This study has also indicated the types of recommendations, based on the 
different physiological systems and drug classes, which are more likely to be of high clinical 
relevance; these findings may aid in the ranking of medication recommendations in future research. 
Future computerised interventions aimed at medication optimisation in multimorbid older adults must 
be meticulously designed to provide tailored advice specific to individual patients’ pharmacotherapy, 
thereby minimising the number of recommendations that are irrelevant or of low clinical relevance. 
Achieving greater proportions of recommendations that are of high clinical relevance should facilitate 
implementation by prescribers, resulting in the resolution of PIP issues and improved clinical 
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Table 1: Prescriber implementation rates of recommendations categorised according to their degree of clinical relevance. 
 
Degree of clinical 
relevance 
 
0 - Adverse significance 
 
1 - No clinical relevance 
 
2 - Possibly low relevance 
 
3 - Possibly important 
relevance  
 
4 - Possibly very important 
relevance 
 





































0 versus 2,3,4:  p < 0.05‡ 1 versus 2,3,4:  p < 0.05‡ 2 versus 0,1,3,4:  p < 0.05 3 versus 0,1,2,4:  p < 0.05 4 versus 0,1,2,3:  p < 0.05 - 
 
Most common type 
of STOPP/START 
recommendation 
within the category 
 
 
Possible reason for 
assigning this degree 
of relevance: 
 
START A3: Antiplatelet therapy 
(aspirin or clopidogrel or 
prasugrel or ticagrelor) with a 
documented history of coronary, 
cerebral or peripheral vascular 
disease. (n = 22; 48.9%) 
Recommendation to start an 
antiplatelet but patient already 
prescribed an anticoagulant – 
increased risk of bleeding.  
 
STOPP J3: Beta-blockers in 
diabetes mellitus with frequent 
hypoglycaemic episodes (risk of 
suppressing hypoglycaemic  
symptoms). (n = 40; 20.1%) 
 
Recommendation triggered for all 
diabetic patients prescribed beta-
blockers. Patient not presenting 
with frequent hypoglycaemic 
episodes – therefore, not relevant. 
 
STOPP A2: Any drug prescribed 
beyond the recommended duration, 
where treatment duration is well 
defined. (n = 104; 32.5%) 
 
 
Recommendation to stop long-term 
high-dose PPI. Not of high clinical 
relevance in a patient who may have 
a more serious acute issue to be dealt 
with.   
 
START A6: Angiotensin 
Converting Enzyme (ACE) 
inhibitor with systolic heart 
failure and/or documented 
coronary artery disease.             
(n = 24; 8.4%) 
Recommendation may be 
possibly important in reducing 
the risk of cardiovascular 
events in those with coronary 
artery disease.  
 
START A1: Vitamin K 
antagonists or direct thrombin 
inhibitors or factor Xa inhibitors 
in the presence of chronic atrial 
fibrillation. (n = 13; 17.1%) 
 
Recommendation to start an 
anticoagulant in a patient with 
atrial fibrillation may be possibly 
very important in the prevention 
of future stroke. 
- 
 
* Includes all recommendations with data available regarding prescriber implementation    
† Difference in prescriber implementation rates between categories of clinical relevance; statistically significant difference observed where p < 0.05 




















0 - Adverse 
significance 
 
1 - No clinical 
relevance 
 
2 - Possibly low 
relevance 
 






















Difference between proportion of START and STOPP at 
different categories of relevance* 
 




* Statistically significant difference where p < 0.05       
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Supplementary Appendix 1 – Reasons for criterion exclusion in evaluation of clinical relevance 
 
As part of the intervention, recommendations START I1 and START I2 (suggesting to ensure patients 
received influenza and pneumococcal vaccinations) appeared on all reports. These recommendations 
were excluded from the assessment of clinical relevance and implementation as it was not 
documented if all these patients had been vaccinated or not.  
STOPP A1 (a recommendation suggesting to stop “Any drug prescribed without an evidence-based 
clinical indication”) was also written on the report but this too could not be assessed for clinical 
relevance or implementation, as the indication was not clear for all medications.  
Therefore, of the 114 STOPP/START criteria (version 2), recommendations based on 3 criteria were 
excluded from our analysis.  
 
However, it should also be noted that two slight software modifications were made a few weeks into 
patient recruitment: 
- START A2 (“Aspirin [75 mg – 160 mg once daily] in the presence of chronic atrial fibrillation, 
where Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors are 
contraindicated”) was initially triggering as a stand-alone recommendation, but later appeared as a 
joint recommendation along with START A1 (“Vitamin K antagonists or direct thrombin inhibitors 
or factor Xa inhibitors in the presence of chronic atrial fibrillation”). Therefore, relevance and 
implementation data are only available for START A1 from that point on.  
- STOPP A3 (a recommendation to stop “Any duplicate drug class prescription”) was initially 
appearing on reports. However, due to high numbers of STOPP A3 recommendations being produced 




Supplementary Appendix 2 – Inter-rater Reliability Assessment 
A convenience sample of three pharmacists and three physicians (one consultant geriatrician, and two 
specialist registrars – i.e. senior residents – in geriatric medicine) were invited to participate. Raters 
were purposively selected on the basis of their involvement with the SENATOR project and/or the 
OPERAM project, another multi-centre RCT in which the intervention similarly included the 
provision of computer-generated medication recommendations based on STOPP/START criteria 
version 2 (https://operam-2020.eu/index.php?id=1488).  
Twenty intervention cases were selected at random, representing approximately 10% of intervention 
patients recruited at CUH. Details of this random selection can be found below. The study’s 
objectives were explained to each rater, and all raters were supplied with instructions on how to assess 
the clinical relevance of the recommendations, whereby the rater had to independently assign a code 
of 0-5 for each SENATOR-generated STOPP/START recommendation based on the clinical 
relevance categories described previously. Three sample cases (all based on real intervention patients) 
were provided with the clinical relevance codes already assigned to the recommendations, and with a 
rationale given as to why each code was chosen by the pharmacist-physician pair for each patient. The 
twenty clinical cases were presented in a standardised format (see Supplementary Appendix 3) to 
include age, sex, comorbidities, medicines prescribed at the time of randomisation, laboratory test 
results, and any other important information required to facilitate the raters in evaluating the clinical 
relevance of the STOPP/START recommendations. 
Random Selection of 20 Intervention Cases for Inter-rater Reliability Assessment  
A list of all intervention patients in the study site was divided into four according to the date of 
recruitment to ensure patient cases were obtained from different times during the RCT.  
An independent researcher (external to this study) rearranged the four lists of patient numbers into a 
random order. The first five patients with at least three STOPP/START recommendations in each list 
were chosen as the cases in the inter-rater reliability study. Thus, twenty intervention patients’ cases 
were selected at random. 
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Supplementary Appendix 3 – Standardised Case Format for Inter-rater Reliability Assessment 
 
Age:    80  
Sex:    Female  
Date of recruitment: 11/2017 
Presenting Condition:  Patient presenting with urosepsis. Patient fell during the night before 
admission to hospital when on her way to the toilet with bruising to right arm 




3. Chronic ischaemic heart disease 
4. Osteoarthritis 
5. Osteoporosis 
6. Neck of femur fracture 2014 
Medications:   
1. Tinzaparin 3500 units OD SC           On since admission 
2. Piperacillin/Tazobactam 4.5g TDS IV           On since admission  
3. Aspirin 75mg OD 
4. Ramipril 2.5mg OD 
5. Atorvastatin 20mg OD 
6. Zolpidem 10mg NOCTE            On for 6 – 12 months 
7. Paracetamol 1g QDS IV/PO PRN    
 




Sodium (mmol/L) 140 
Potassium (mmol/L) 4.1 
Corrected calcium (mmol/L) 2.31 
Creatinine (micromoles/L) 63 
eGFR (MDRD) ml/min/1.73m2 113 
Haemoglobin (g/dl) - 
Platelets x 109 370 
INR - 
• Blood Pressure: 124/79 mmHg 
• Heart Rate: 76 beats/min 
 
• Patient does not have a history of recurrent falls. 
 
• On at home but not charted:                                 
Calcium/Vitamin D3 500mg/400 units  1 tablet BD          






Drug Recommendation Clinical 
Relevance 
Zolpidem 
Hypnotic Z-drugs e.g. zopiclone, zolpidem, zaleplon (may cause protracted 
daytime sedation, ataxia). 
 
 
Any drug prescribed beyond the recommended duration, where treatment 









Beta-blocker with ischaemic heart disease. 
 
 
Vitamin D and calcium supplement in patients with known osteoporosis and/or previous fragility 
fracture(s) and/or (Bone Mineral Density T-scores more than -2.5 in multiple sites). 
 
 
Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, strontium ranelate, teriparatide, 
denosumab) in patients with documented osteoporosis, where no pharmacological or clinical status 
contraindication exists (Bone Mineral Density T-scores -> 2.5 in multiple sites) and/or previous 
history of fragility fracture(s). 
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STOPP A2 1 8 104 17 4 134 
STOPP A3 - 20 - - - 20 
STOPP B1 - 2 - - - 2 
STOPP B3 - 2 - 1 - 3 
STOPP B5 - 5 1 - - 6 
STOPP B6 2 2 - 1 - 5 
STOPP B7 7 10 6 3 - 26 
STOPP B8 - - 3 2 1 6 
STOPP B9 - 1 - - - 1 
STOPP B11 - - 2 1 1 4 
STOPP B12 - - 2 - - 2 
STOPP C3 3 8 1 5 - 17 
STOPP C5 2 - - 2 - 4 
STOPP C6 1 4 - 1 - 6 
STOPP C10 - - - 1 5 6 
STOPP C11 - - - - 1 1 
STOPP D2 - 1 1 1 - 3 
STOPP D4 - 1 1 - - 2 
STOPP D5 - - 13 9 2 24 
STOPP D8 - - 5 13 - 18 
STOPP D9 - 1 - - - 1 
STOPP D10 - 2 1 1 1 5 
STOPP D11 - 4 - - - 4 
STOPP D12 - - - 9 - 9 
STOPP D14 - - 1 20 - 21 
STOPP E3 - 1 1 - - 2 
STOPP E6 - - - - 1 1 
STOPP F2 1 - 15 - - 16 
STOPP F3 - - 3 2 3 8 
STOPP G1 - 1 - - - 1 
STOPP G2 - - 1 - - 1 
STOPP G4 - - 1 - - 1 
STOPP H4 - 2 1 - - 3 
STOPP H5 - 2 - 1 - 3 
STOPP H6 - - 1 - - 1 
STOPP H7 - - - 1 - 1 
STOPP H8 - - - 7 - 7 
STOPP H9 - - - 2 - 2 
STOPP I1 - - - 10 - 10 
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STOPP I2 - 1 - 4 - 5 
STOPP J3 - 40 1 - - 41 
STOPP K1 - - 13 10 8 31 
STOPP K2  - 1 2 3 1 7 
STOPP K3 1 1 3 11 - 16 
STOPP K4 - - 10 5 1 16 
STOPP L1 - 4 5 2 - 11 
STOPP L2 1 2 4 10 2 19 
STOPP L3 - 2 6 4 1 13 
STOPP N - 1 4 12 - 17 
START A1 1 - 1 12 13 27 
START A2 - 1 - 1 1 3 
START A3 22 15 3 4 3 47 
START A4 - 5 4 4 3 16 
START A5 - 6 12 11 4 33 
START A6 - 2 21 24 3 50 
START A7 2 1 5 5 - 13 
START A8 - - 8 5 1 14 
START B1 - 1 1 - 2 4 
START B2 - 1 1 2 2 6 
START B3 - 5 - - - 5 
START C1 - - - - 1 1 
START D2 - - 1 - - 1 
START E1 - 3 3 1 - 7 
START E2 - - - - 1 1 
START E3 - - - 5 2 7 
START E4 - 2 6 5 1 14 
START E5 - - - 8 3 11 
START E6 - - 1 2 - 3 
START F1 - 1 1 10 1 13 
START G1 - 8 - 1 - 9 
START G2 - 12 8 1 - 21 
START H1 - 4 3 - 1 8 
START H2 1 3 29 13 2 48 
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Supplementary Table 2: Clinical relevance of recommendations based on drug class 
 





























PPIs 2 8 96 - - 106 
Benzodiazepines - - 37 27 11 75 
ACE-Inhibitors and/or ARBs 1 3 25 38 5 72 
Beta blockers 2 41 14 10 1 68 
Opioids 1 13 19 16 7 56 
Laxatives 1 5 29 13 2 50 
Diuretics 9 13 11 6 1 40 
Antihistamines - - 3 35 - 38 
Statins - 6 12 11 4 33 
Antipsychotics - 4 3 21 2 30 
Z-drugs - - 18 8 2 28 
Bone anti-resorptive,  anabolic 
agents 
- 2 7 11 2 22 
5-alpha reductase inhibitors - 12 8 1 - 21 
Alpha-1 Receptor blockers - 10 - 9 - 19 
Vitamin D +/- Calcium - - - 13 5 18 
Drugs for obstructive airways 
disease 
- 9 2 2 4 17 
Antihypertensives (START A4) - 5 4 4 3 16 
Anticholinergics - 1 3 11 - 15 
Miscellaneous cardiac drugs - 8 2 2 - 12 
Other miscellaneous agents - 1 4 3 3 11 
Antidepressants - 3 4 1 - 8 
Corticosteroids - 4 3 1 - 8 
NSAIDs - - - 2 6 8 
Calcium channel blockers - 2 2 3 - 7 
DMARDs - 3 3 1 - 7 
Anti-diabetic drugs - 4 - - 1 5 
Drugs to treat gout or 
hyperuricaemia 
- - 3 2 - 5 
Oxygen - 5 - - - 5 
Anti-dementia drugs  - 4 - - - 4 
Drugs for urinary 
frequency/incontinence 
 
- - 2 2 - 4 
TOTAL 45 199 320 285 76 925 
 
PPI: Proton pump inhibitors; ACE: Angiotensin Converting Enzyme; ARB: Angiotensin Receptor Blocker; NSAIDs: Non-steroidal anti-
inflammatory drug; DMARD: Disease-modifying anti-rheumatic drug. 
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Supplementary Appendix 6 – Reasons for lack of data on prescriber implementation 
 
Data on prescriber implementation was unavailable for 41/925 (4.4%) recommendations, which 
includes the following:  
- all STOPP A3 recommendations, which were later removed from the intervention (n = 20),  
- two patients without implementation data in the electronic case report form (n = 15),  
- all START B3 recommendations, as there was no data on oxygen prescribing (n = 5), and  
- one STOPP N recommendation that triggered inappropriately (n = 1). 
 
 
